ТЕРИФЛУНОМИД – НОВЫЙ ТАБЛЕТИРОВАННЫЙ ПРЕПАРАТ ДЛЯ ЛЕЧЕНИЯ РЕМИТИРУЮЩЕГО РАССЕЯННОГО СКЛЕРОЗА (ОБЗОР)

This review includes results of experimental and clinical studies of new oral drug teriflunomide for pathogenetic treatment of multiple sclerosis (MS). Given the mechanism of action, clinical data of the studies II and III phases of clinical efficacy, tolerability and safety. Discusses the place of teriflunomide in pathogenetic treatment of MS.